BioAge Labs Inc Dossier
Qualitative Analysis
Business overview
BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic product candidates for metabolic and cardiometabolic diseases, such as obesity, by targeting the biology of human aging. Founded in 2015, the company leverages its proprietary discovery platform built on human longevity data and differentiated human datasets to identify molecular changes that drive aging and translate them into targeted therapies. Its lead clinical program is BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk reduction and retinal diseases. Additionally, the company is developing long-acting injectable and oral small-molecule APJ agonists for obesity.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing BGE-102, an oral, brain-penetrant NLRP3 inhibitor, through the QUELL-CV Phase 2 proof-of-concept trial. The trial is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating three once-daily doses (30 mg, 60 mg, and 90 mg) in approximately 160 adults with obesity and elevated hsCRP.
Expected impact: Aims to demonstrate stable reductions in inflammatory biomarkers (hsCRP, IL-6, fibrinogen) and expand the safety and tolerability dataset to support Phase 3 dose selection.
Expanding the clinical development of BGE-102 into retinal diseases, starting with a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME). The study will evaluate BGE-102 as a monotherapy, VEGF monotherapy, and VEGF plus BGE-102 combination therapy.
Expected impact: Aims to demonstrate therapeutic retinal exposure and anti-inflammatory efficacy (measuring intraocular IL-6) to establish BGE-102 as a multi-indication therapy.
Developing structurally distinct, next-generation apelin receptor (APJ) agonists for obesity following the discontinuation of azelaprag in late 2024. This includes advancing a novel APJ agonist nanobody under an exclusive option agreement with JiKang Therapeutics and progressing a proprietary portfolio of orally active APJ agonists.
Expected impact: Aims to deliver a potent, safe oral or parenteral APJ agonist to promote muscle metabolism and prevent muscle atrophy in combination with incretin therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A multi-year research collaboration focused on identifying and validating novel therapeutic drug targets for age-related diseases by investigating biological mechanisms that drive aging and mediate the beneficial effects of physical exercise.
Terms: BioAge received upfront payments and research funding of up to $20 million, and is eligible to receive up to $530 million in future long-term research, development, and commercial milestones, plus reciprocal success milestones and tiered royalties.
A collaboration focused on the discovery and development of therapeutic antibodies targeting novel metabolic aging targets identified through BioAge's proprietary human-first discovery platform.
Terms: Specific financial terms were not publicly disclosed.
Jointly advancing a novel APJ agonist nanobody demonstrating at least 10-fold greater potency than apelin toward IND-enabling studies, providing BioAge with an exclusive option to license the asset.
Terms: Specific financial terms were not publicly disclosed.
Collaborating to comprehensively profile and analyze samples from the HUNT Biobank in Norway, generating molecular insights from more than 17,000 individual samples to identify new drug targets for age-related diseases.
Terms: Specific financial terms were not publicly disclosed.